Pascal Biosciences Discovers Cannabinoids Activate the Major Histocompatibility Complex to Aid Cancer Treatment
23 September 2019 - 2:30PM
Pascal Biosciences Inc.
(
TSX.V:PAS) (“Pascal” or the “Company”) today
revealed the mechanism whereby cannabinoids may directly aid in
cancer treatment.
Specific cannabinoids identified by Pascal
scientists enhance the immunogenicity of tumour cells, rendering
them more susceptible to recognition and elimination by the immune
system. Besides combatting infection, one of the key roles of the
immune system is to identify and eliminate cancer cells that can
arise during the normal course of cell growth in healthy
individuals. The Major Histocompatibility Complex (“MHC”) is the
cellular machinery that flags tumour cells for the immune system.
However, most metastatic tumour cells have lost their MHC
expression, and thus escape immune system killing. Specific
cannabinoids reactivate MHC expression and may restore immune cell
destruction of tumours. This could aid cancer treatment,
particularly by boosting the efficacy of checkpoint inhibitors, an
exciting form of immunotherapy that is only effective in a fraction
of patients.
Pascal first discovered that cannabinoids can
stimulate the immune system to destroy tumour cells in February
2018. Since then, Pascal has tested over 400 natural and synthetic
cannabinoids in Pascal’s proprietary assays. Pascal has further
studied the immune activities that occur with cannabinoid
treatment.
Pascal CEO Patrick Gray will present these
exciting results at the CannMed 2019 Conference – Inspiring
Science, Community & Hope – taking place September 23-24 at the
Pasadena Convention Center in Pasadena, CA.
“We have made great progress since first
announcing our results last year. We now have a much better
understanding of the interplay between cannabinoids, the immune
system, and cancer,” said Dr. Gray. “This work has enabled us to
choose a specific cannabinoid with a good safety profile for human
testing. We are nearing clinical development and we have the
scientific understanding and patent protection to move our product
forward.”
About Pascal Biosciences Inc.
Pascal is a biotechnology company focused on
advancing innovative approaches for the treatment of cancer
including cannabinoid-based therapeutics and targeted therapies.
The Company’s leading portfolio comprises a small molecule
therapeutic, PAS-403, that is advancing into clinical trials for
the treatment of glioblastoma, and PAS-393, an immuno-stimulatory
cannabinoid to be used in combination with checkpoint inhibitor
therapy. In addition, Pascal is developing a B-cell targeted
antibody for acute lymphoblastic leukemia. For more information,
visit www.pascalbiosciences.com.
Investors: invest@pascalbiosciences.com
Media Contact: Julie
Rathbuninfo@pascalbiosciences.com Tel: 206-769-9219
DISCLAIMER Certain statements in this press
release contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities
legislation that may not be based on historical fact, including
without limitation statements containing the words “believe”,
“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”,
“intend”, “expect” and similar expressions. Such forward-looking
statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
events or developments, or industry results, to be materially
different from any future results, events or developments express
or implied by such forward-looking statements or information. Such
factors include, among others, our stage of development, lack of
any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining
regulatory approval to market our products, the ability to protect
our intellectual property, dependence on collaborative partners and
the prospects for negotiating additional corporate collaborations
or licensing arrangements and their timing. Specifically, certain
risks and uncertainties that could cause such actual events or
results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results
expressed or implied by such statements and information include,
but are not limited to, the risks and uncertainties that: products
that we develop may not succeed in preclinical or clinical trials,
or future products in our targeted corporate objectives; our future
operating results are uncertain and likely to fluctuate; we may not
be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing
arrangements; we may not be able to establish marketing and the
costs of launching our products may be greater than anticipated; we
have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and
other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com.
Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements and information,
which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are
based on our current expectations and we undertake no obligation to
revise or update such forward- looking statements and information
to reflect subsequent events or circumstances, except as required
by law.
“Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release”
Pascal Biosciences (TSXV:PAS)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Pascal Biosciences (TSXV:PAS)
Historical Stock Chart
Von Dez 2023 bis Dez 2024